Mark Ayers
Merck & Co., Inc., Rahway, NJ, USA (United States) · 115 works · 15,852 citations · h-index 40
Top works
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
- Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer
- The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
- Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.
- Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.
- Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
- Comparison of the Predictive Accuracy of DNA Array-Based Multigene Classifiers across cDNA Arrays and Affymetrix GeneChips
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer
- Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials
- Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475).
- Breast cancer biomarkers and molecular medicine
- OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC
- Clinical Application of cDNA Microarrays in Oncology
- Breast cancer biomarkers and molecular medicine: part II